Key Takeaways NVS, ALG, MT, BILI and STRL offer low leverage with strong earnings growth prospects. The stocks offer defensive positioning amid market uncertainty and regulatory shifts. Each stock reflects a favorable Zacks Rank and VGM Score.Wall Street ended the first day of July 2025 on a mixed note. While the S&P 500 and Nasdaq suffered a fall, the Dow Jones Industrial Average gained a little. The contrasting movement witnessed across the three major stock indices of the U.S. equity market was due to ...

Core Viewpoint - Novartis (NVS) has shown strong stock performance, with a 3.7% increase over the past month and a 24.4% gain since the beginning of the year, outperforming the Zacks Medical sector and the Zacks Large Cap Pharmaceuticals industry [1][2]. Financial Performance - Novartis has consistently exceeded earnings expectations, reporting an EPS of $2.28 against a consensus estimate of $2.12 in its last earnings report [2]. - For the current fiscal year, Novartis is projected to achieve earnings of $8.77 per share on revenues of $54.38 billion, reflecting a 12.29% increase in EPS and a 7.31% increase in revenues [3]. - The next fiscal year forecasts an EPS of $9.05 and revenues of $55.35 billion, indicating year-over-year changes of 3.26% and 1.79%, respectively [3]. Valuation Metrics - Novartis currently trades at 13.8 times the current fiscal year EPS estimates, slightly below the peer industry average of 13.9 times [7]. - The stock's trailing cash flow basis is at 11.3 times, matching the peer group's average [7]. - The PEG ratio stands at 1.74, which does not place the company among the top tier from a value perspective [7]. Zacks Rank and Style Scores - Novartis holds a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts [8]. - The company has a Value Score of B, a Growth Score of B, and a Momentum Score of F, resulting in a combined VGM Score of B [6][8]. - Given the Zacks Rank and Style Scores, Novartis appears to have potential for further stock price appreciation in the near term [8].

2025年RDC药物最新进展。在医学不断进步的今天，肿瘤治疗领域持续探索更精准、高效且低毒的治疗方法。放射性核素偶联药物（RDC）作为核药领域 的前沿方向，凭借其精准靶向、高效杀伤和诊疗一体化的独特优势，近年来正在全球医药领域掀起创新浪潮。 一、厚积薄发，RDC药物的崛起 自1896年贝克勒尔首次发现放射性物质，开启了放射性核素在医学领域应用的探索之旅，至今已逾一个多世纪。在这漫长的发展历程中，放射性核素在医学 领域的应用范围不断拓展，尤其是在核药领域取得了显著进展。其中，诊断用途的核药在核药应用市场中占据主导地位，占比超过九成。 进入21世纪，传统核药如碘-131（碘化钠）、镭-223（氯化镭）等在临床治疗中得到广泛应用。碘-131自1941年首次用于治疗甲状腺功能亢进取得良好效果 后，1946年又被应用于甲状腺癌的治疗，大量临床研究证实其治疗分化型甲状腺癌转移灶疗效好、操作简便且副作用小。2013年，拜耳的Xofigo（氯化镭 [223Ra]注射液）成功获得FDA批准上市，成为历史上首个治疗用核药，用于治疗前列腺癌骨转移。 放射性药物分类及特点 图片来源：摩熵咨询《中国放射性药物产业白皮书》 近年来，以镥 ...

早 报 精 选 1、 鼓励外资企业利润再投资，三部门发布税收优惠政策。 2、金融服务新型工业化增量政策酝酿出台。 3、加拿大政府关闭海康威视在加业务，商务部回应。 4、创业板明确"轻资产、高研发"标准。 5、国家外汇管理局日前已向部分符合条件的合格境内机构投资者（QDII）发放投资 额度合计30.8亿美元，旨在进一步支持QDII机构依法合规开展跨境投资业务，在有效 防范风险的前提下，有序满足境内居民合理对外投资需求。 行 业 新 闻 1、 据悉，进一步深化金融服务新型工业化的相关政策有望研究出台。去年4月，国家 金融监督管理总局、工业和信息化部、国家发展改革委已联合发布《关于深化制造业 金融服务助力推进新型工业化的通知》。增量政策预计将引导更多金融资源用于促进 科技创新等领域。 2、深交所发布创业板"轻资产、高研发投入"认定标准。在"轻资产"认定标准方面， 根据指引，要求公司最近一年末固定资产、在建工程、土地使用权、使用权资产、长 期待摊费用以及其他通过资本性支出形成的实物资产合计占总资产比重不高于20%。 在"高研发投入"认定标准方面，根据指引，要求公司最近三年平均研发投入占营业收 入比例不低于15%；或最 ...

以下文章来源于IN咖 ，作者聪明投资者 IN咖 . 多视角关注优秀投资人和企业家 "现在，所有跨国大型药企在审视全球创新格局时，已经开始把上海视作与波士顿、圣地亚哥等传统创新中心并 列的'新核心'来看待。" 6月25日放出的Good company播客节目，挪威主权财富基金掌门人尼古拉·坦根（Nicolai Tangen）邀请了全球创 新药巨头诺华（Novartis）首席执行官万思瀚（Vasant Narasimhan），共同探讨制药业的技术拐点、AI驱动的新 药发现，以及欧洲与中国在全球医药版图中的角色变迁。 作为市值约 2330亿美元的纯创新药龙头，诺华稳居全球药企第一梯队。 万思瀚受过医生训练，曾在发展中国家一线抗击结核病和疟疾，后来一路走到全球最大医药公司之一的掌门 人位置。 自 2018年万思瀚接棒以来，公司剥离爱尔康与山德士等非核心资产后，核心估值从约2100亿美元提升至 当下水平；若将已分拆业务重新计入，总体价值约翻至3300亿美元区间。 据坦根介绍， 挪威主权财富基金持有诺华约 2.3%的股份，市值超过50亿美元 。 谈到备受关注的 AI 在创新药研发中的运用， 万思瀚直言： "真正的问题是， ...

Core Insights - The 2025 Global Pharmaceutical Companies Top 50 list has been released, with Johnson & Johnson's Innovative Medicines leading with $55.7 billion in sales, followed by AbbVie and Merck [1][2] - Novo Nordisk enters the top ten for the first time due to its GLP-1 drug semaglutide, while Merck rises from fourth to third place, driven by the strong performance of its drug Keytruda [1][3] - Six Chinese companies made the list, marking a significant increase, with BeiGene and Huadong Medicine making their debut [1][5] Group 1: Rankings and Sales Performance - The list is based on prescription drug sales, core product revenue, and R&D investment, reflecting significant changes in the pharmaceutical industry [2] - Merck's Keytruda has received FDA approval for 40 indications and is projected to generate $29.482 billion in sales in 2024, accounting for approximately 54.28% of Merck's prescription drug revenue [3] - Novartis dropped from third to seventh place, with a prescription drug sales forecast of $50.191 billion for 2024, facing challenges due to patent expirations [4] Group 2: Chinese Pharmaceutical Companies - Six Chinese companies ranked in the top 50, the highest number in five years, although all ranked below 30 due to smaller market sizes [5][6] - Chinese innovation in pharmaceuticals is gaining recognition, with significant presentations at major conferences like AACR and ASCO [5] - The future outlook for Chinese companies in the global pharmaceutical landscape appears promising, with expectations of increased rankings and numbers by 2030 [5] Group 3: Market Trends and Projections - The GLP-1 class of drugs is expected to dominate prescription drug sales, with projections indicating that Eli Lilly will become the top-selling pharmaceutical company by 2030 [4] - The ADC (antibody-drug conjugate) market is expanding, with significant transactions and research presentations from Chinese companies at international conferences [6] - The overall sentiment in the industry is improving, with a focus on the value of Chinese innovative drugs despite previous financing challenges [6]

Core Insights - ProFound Therapeutics has announced a four-year collaboration with Novartis to develop novel therapeutics for cardiovascular disease using its ProFoundry™ Platform [1][3] - The collaboration includes $25 million in upfront and near-term milestone payments, with potential downstream milestone payments of $750 million per target [1][3] Company Overview - ProFound Therapeutics focuses on discovering proteins within the expanded human proteome to develop first-in-class medicines for various diseases [4] - The ProFoundry™ Platform integrates multi-layered biological data and advanced computational tools to identify and validate novel proteins as drug targets [2][4] Collaboration Details - The partnership aims to leverage ProFound's capabilities in identifying novel proteins and Novartis' expertise in cardiovascular drug development [1][3] - The collaboration is expected to accelerate the discovery of new therapeutic targets and support the development of transformative therapies for cardiovascular diseases [3]

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis. “We are pleased to complete this transaction and take the next step in advancing clinical development for a potential first-in-class ...

Core Insights - The article emphasizes the importance of maintaining investment positions and avoiding losses, highlighting that business fundamentals can change significantly from quarter to quarter [1]. Summary by Sections - The article discusses how shifts in business fundamentals can impact investment strategies over time [2].

李尧表示："作为全球医药健康行业领跑者，诺华始终秉承'以患者为中心'的核心理念，希望通过创新 和前沿技术创想医药未来。人工智能与生成式生物学不仅是研发工具，更是开启生物医学新纪元的催化 剂。我们也坚信，借助这些前沿技术的创新力量，联合全球特别是中国本土的创新资源，将会为药物研 发带来更多革新，为患者创造更多福祉。" 通过整合海量数据（603138）、结合人工智能的深度学习和高效分析能力，并将其融入药物研发进程， 诺华正逐步成为生成式生物学前沿创新的核心推动者之一。此前，诺华已经与微软建立合作，将机器学 习应用于药物研发——利用人工智能更有效地为患者开发新疗法。 2025年6月24日至26日，世界经济论坛第十六届新领军者年会（夏季达沃斯论坛）在天津举行。本届年 会以"新时代企业家精神"为主题，汇聚来自全球1700余位政商领袖、专家学者共同探讨如何以企业家精 神和创新驱动经济增长与探索产业升级新路径等话题。诺华中国区总裁兼董事总经理李尧受邀参会，并 围绕"'智造'为医药研发带来革新"等话题分享见解。 "智造"刷新医药领域"效率公式" 随着人工智能等前沿技术的不断进展，医药领域也正处于关键转折点，以药物研发为例，传 ...